Advances in Blood Cancers: How We Define Success
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 December 2024 | Viewed by 52
Special Issue Editors
Interests: CLL; prognostic factors; novel agents; lymphoproliferative disorders; clinical trials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent years have witnessed significant research-driven advancements in the treatment of blood cancers. Such developments have been driven by innovative cancer therapies and drug combinations that have rapidly become established as new standards of care in haematology treatment. However, to further enhance blood cancer cure rates, identifying the somatic drivers and molecular targets which drive tumour progression and modulate the immune system to bolster the body’s innate defences against cancer is essential.
With the advent of next-generation modalities, including antibody–drug conjugates (ADCs), bispecific antibodies, T-cell engagers, cell therapies and epigenetic modifiers, we are unlocking novel avenues to further target haematological cancers. This allows the haematology community to construct tailored combination treatments based on individual patient’s disease characteristics. For instance, we are witnessing the potential of combining immuno-oncology agents—such as bispecific antibodies, T-cell engagers and cell therapies—with modalities like ADCs to elicit more robust and enduring responses in the clinic.
Across haematological malignancies, these concepts have been applied to patients with lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and Hodgkin lymphoma, acute myeloid leukaemia, and multiple myeloma (MM) and have resulted in significant improvements in both life expectancy and the quality of life of patients.
This Special Issue will highlight the current state of the art of novel therapies that have made substantial contributions to modifying the natural history of haematological cancers, where clinical endpoint improvements have truly marked success.
Dr. Stefano Molica
Dr. David Allsup
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood cancers
- research-driven advancements
- cure rates
- novel agents
